期刊文献+

反相高效液相色谱荧光检测法测定血浆中利扎曲普坦浓度 被引量:2

Determination of rizatriptan in human plasma by RP-HPLC with fluorescence detection
下载PDF
导出
摘要 目的:建立反相高效液相色谱荧光检测法测定血浆中利扎曲普坦(RZT)浓度。方法:采用 Luna C_8(2)分析柱(250mm×4.6m,5μm),柱温为40℃,流动相为0.02 mol·L^(-1)磷酸二氢钾-乙腈-甲醇(87:10:3),流速1.0mL·min^(-1),样品血浆在碱性条件下用二氯甲烷旋涡混合提取浓集后用蒸馏水溶解进样,用荧光检测器(λ_(ex)290nm,λ_(em)356nm)检测,以佐米曲普坦作内标,按内标法定量。结果:标准曲线在0.25~80μg·L^(-1)范围内有良好线性,最低检测限为0.25μg·L^(-1),RZT 及内标的保留时间分别为7.0min 和8.6min,日内和日间 RSD 均小于9%,方法回收率在92%~111%。结论:本法具有快速简便,灵敏准确等特点,适用于利扎曲普坦血药浓度测定及药代动力学研究。 Objective:To establish an RP - HPLC method with fluorescence detection for the determination of rizatriptan (RZT) in human plasma. Methods:A fluorescence detector and Luna Cs (2) analysis column (250 mm × 4.6 mm ,5μm) were used. The alkalinized plasma sample was extracted with 3.0 mL dichloromethane. After evaporation of the organic layer,the residue was dissolved in distilled water and injected onto the column. The mobile phase of 0. 02 mol·L^1 potassium dihydrogen phosphate- acetonitrile- methanol (87: 10: 3) was pumped at 1.0 mL · min^-1 through the column. The detector at high sensitivity was set at λex 290 nm and λem 356 nm. Results:The retention times for RZT and internal standard (zolmitriptan) were 7.0 min and 8.6 rain, respectively. The standard curve was linear over the concentration range of 0. 25 to 80μg · L^-1. The lowest concentration of detection in plasma was 0. 25 μg · L^-1. The method recoveries were 92% - 111% ; the intra -day RSD and inter - day RSD were less than 9%. Conclusion:This method is found to be simple, rapid, sensitive and accurate for determination of RZT in human plasma.
出处 《药物分析杂志》 CAS CSCD 北大核心 2006年第1期7-9,共3页 Chinese Journal of Pharmaceutical Analysis
关键词 利扎曲普坦 血药浓度 反相高效液相色谱法 rizatriptan (RZT) plasma drug concentration RP - HPLC
  • 相关文献

参考文献2

  • 1McLoughlin DA,Olah JD, Ellis JD,et al. Quantitation of the 5HTID agonists MK-462 and sumatriptan in plasma by liquid chromatography- atmospheric pressure chemical ionization mass spectrometry. J Chromatogr A, 1996, 726 ( 1 ) : 115
  • 2Goldberg MR, Lowry RG, Musson DG, et al. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine.J Clin Pharmacol, 1999,39 : 192

同被引文献12

  • 1高旭光.偏头痛的治疗[J].医师进修杂志,2005,28(4):10-12. 被引量:3
  • 2Hirohisa Okuma, Yasuhisa Kitagawa, Shigeharu Takagi. Clinical efficacy of rizatriptan for patients with migraine: efficacy of drug therapy for migraine accompanied by tension headache - like symptoms, focusing on neck stiffness. J Headache Pain,2005, (6) :455
  • 3Lee Y, Conroy JA, Stepanavage ME, et al. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. Br J Clin Pharmacol, 1999,47 : 373
  • 4Vyas Kamlesh P, Halpin Rita A,Geer Leslie A,et al. Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. Drug Metab Dispos,2000,28(1 ) :89
  • 5Chen Jun, Jiang Xinguo, Jiang Wenming, et al. Liquid chromatographic method for the determination of rizatriptan in human plasma. J Chromatogr B,2004,805 : 169
  • 6Lipton RB, Buse DC, Saiers J, et al. Frequency and burden of headache-related nausea: results from the American Migraine Prevalence and Prevention (AMPP) study [J]. Headache, 2013, 53 (1) : 93--103.
  • 7Prcls M, Woertz C, Kleinebudde P, et al. Oromucosal film preparations: classification and characterization methods [J]. Expert Opin DrugDeliv, 2013, 10 (9): 1303--1317.
  • 8Preis M, Gronkowsky D, Grytzan D, et al. Comparative study on novel test systems to determine disintegration time of orodispersible films [J]. J Pharm Pharmacol, 2014, 66 (8): 1102--1111.
  • 9Xia YR, Chen F, Zhang HP, et al. A new method for evaluating the dissolution of orodispersible films [J]. Pharm Dev Technol, 2015, 20 (3): 375--379.
  • 10陈芳,夏怡然,张惠平,张桦,侯惠民.流延法制备口溶膜剂及其质量评价[J].中国医药工业杂志,2013,44(9):938-942. 被引量:18

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部